Literature DB >> 10951359

Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leukoencephalopathy.

T Kishi1, Y Tanaka, K Ueda.   

Abstract

BACKGROUND: The prognosis of patients with acute lymphoblastic leukemia (ALL) in childhood has improved with intensive chemotherapy. In particular, central nervous system (CNS) leukemia has been well controlled by the presymptomatic administration of intrathecal methotrexate (MTX), high dose systemic MTX, and irradiation. However, the prolonged intrathecal administration and/or the administration of high doses of systemic MTX, especially when combined with irradiation, can lead to leukoencephalopathy (LE), a serious CNS complication of such prophylaxis. Because the mechanisms by which MTX causes this complication have not been elucidated, the authors investigated the transmethylation status of the cerebrospinal fluid (CSF) in two children with ALL and LE to investigate the pathophysiology of that disorder.
METHODS: The levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were measured in the CSF of 2 children with ALL and LE, 7 children with ALL only who were undergoing presymptomatic administration of MTX, and 18 reference children in whom diagnostic lumbar puncture was indicated for other reasons. A sensitive, high performance liquid chromatography (HPLC) method was used with fluorescence detection.
RESULTS: The concentrations of SAM in the CSF were lower in the patients with ALL during treatment with MTX compared with the reference children. The SAM levels in the 2 patients with both ALL and LE were slightly lower than the levels in the 7 patients with ALL only. The SAH concentrations in the CSF were higher in the patients with ALL and LE compared with the patients with ALL only and the reference children. The mean concentration of SAH in the CSF was similar in the reference children to that found in the 7 patients with ALL only. The SAM-to-SAH ratios were lower in the 2 patients with ALL and LE and in the 7 patients with ALL only compared with the reference children. The ratios in the patients with ALL and LE were still lower than in those with ALL only, thus providing supporting evidence of hypomethylation in the 2 patients with ALL and LE.
CONCLUSIONS: The data suggest that the treatment of children with ALL using MTX causes subclinical hypomethylation and that progressive hypomethylation in the CNS, as evidenced in the 2 patients with ALL and LE, may be responsible for the demyelination in the LE induced by MTX. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951359     DOI: 10.1002/1097-0142(20000815)89:4<925::aid-cncr28>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Protein arginine methylation: from enigmatic functions to therapeutic targeting.

Authors:  Qin Wu; Matthieu Schapira; Cheryl H Arrowsmith; Dalia Barsyte-Lovejoy
Journal:  Nat Rev Drug Discov       Date:  2021-03-19       Impact factor: 84.694

Review 2.  Genetic Modulation of Neurocognitive Development in Cancer Patients throughout the Lifespan: a Systematic Review.

Authors:  Charlotte Sleurs; Aline Madoe; Lieven Lagae; Sandra Jacobs; Sabine Deprez; Jurgen Lemiere; Anne Uyttebroeck
Journal:  Neuropsychol Rev       Date:  2019-03-30       Impact factor: 7.444

3.  Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy.

Authors:  Kala Y Kamdar; Kevin R Krull; Randa A El-Zein; Pim Brouwers; Brian S Potter; Lynnette L Harris; Suzanne Holm; Zoann Dreyer; Fernando Scaglia; Carol J Etzel; Melissa Bondy; M Fatih Okcu
Journal:  Pediatr Blood Cancer       Date:  2011-05-25       Impact factor: 3.167

Review 4.  Neurologic complications of chemotherapy for children with cancer.

Authors:  Alyssa T Reddy; Kerry Witek
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

5.  The activities of antioxidant enzymes and the level of malondialdehyde in cerebellum of rats subjected to methotrexate: protective effect of caffeic acid phenethyl ester.

Authors:  Ertugrul Uzar; Hasan Rifat Koyuncuoglu; Efkan Uz; H Ramazan Yilmaz; Suleyman Kutluhan; Serkan Kilbas; Fatih Gultekin
Journal:  Mol Cell Biochem       Date:  2006-05-23       Impact factor: 3.396

6.  Preliminary Results on the Long-Term Effects of Dextromethorphan on MDMA-Mediated Serotonergic Deficiency and Volumetric Changes in Primates Based on 4-[18F]-ADAM PET/MRI.

Authors:  Skye Hsin-Hsien Yeh; Yu-Yeh Kuo; Wen-Sheng Huang; Chuang-Hsin Chiu; Tsung-Hsun Yu; Leo Garcia Flores Ii; Chi-Jung Tsai; Cheng-Yi Cheng; Kuo-Hsing Ma
Journal:  Front Neurosci       Date:  2022-05-19       Impact factor: 5.152

Review 7.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate.

Authors:  Ann M Winter-Vann; Barton A Kamen; Martin O Bergo; Stephen G Young; Stepan Melnyk; S Jill James; Patrick J Casey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-15       Impact factor: 11.205

9.  Methotrexate treatment of FraX fibroblasts results in FMR1 transcription but not in detectable FMR1 protein levels.

Authors:  Cornelia Brendel; Benjamin Mielke; Merle Hillebrand; Jutta Gärtner; Peter Huppke
Journal:  J Neurodev Disord       Date:  2013-09-10       Impact factor: 4.025

Review 10.  Targeting the epigenetic machinery of cancer cells.

Authors:  M F Montenegro; L Sánchez-del-Campo; M P Fernández-Pérez; M Sáez-Ayala; J Cabezas-Herrera; J N Rodríguez-López
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.